ELAVL1 and breast cancer: This dual-nanoparticle design, incorporating distinct peptides and an acidic TME-sensitive PEG derivative, not only mitigates the toxic effects on normal cells but also enhances the specific ligand-receptor binding and uptake of nanoparticles into BC cells, facilitating the release of HuR CRISPR and DTX in the nucleus and cytoplasm.